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ZEBRAFISH MODELS OF HUMAN LEUKEMIA: 
TECHNOLOGICAL ADVANCES AND MECHANISTIC INSIGHTS 
NICHOLAS R. HARRISON 
ABSTRACT 
Improved therapeutic strategies for patients with leukemia remain in great demand and 
beckon better understanding of the mechanisms underlying leukemic treatment resistance 
and relapse. Accordingly, discoveries in leukemic pathophysiology have been achieved in 
various animal models. Danio rerio—commonly known as the zebrafish—is a vertebrate 
organism well suited for the investigation of human leukemia. Zebrafish have a conserved 
hematopoietic program and unique experimental strengths. Recent technological advances 
in zebrafish research including efficient transgenesis, precise genome editing, and 
straightforward transplantation techniques have led to the generation of numerous 
zebrafish leukemia models. Additionally, improved imaging techniques, combined with 
the transparency of zebrafish, have revealed exquisite details of leukemic initiation, 
progression, and regression. Finally, advances in high-throughput drug screening in 
zebrafish are likely to hasten the discovery of novel anti-leukemic agents. Zebrafish 
provide a reliable experimental system for leukemic disease research and one in which 
investigators have accumulated knowledge concerning the genetic underpinnings of 
leukemic transformation and treatment resistance.  Without doubt, zebrafish are rapidly 
expanding our understanding of disease mechanism and are helping to shape therapeutic 
strategy for improved patient outcomes. 
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Introduction 
Leukemias are hematopoietic malignancies and are commonly subdivided into four major 
types—acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute 
myeloid leukemia (AML), and chronic myeloid leukemia (CML)—and other less common 
types including hairy cell leukemia and chronic myelomonocytic leukemia [17]. The 
incidence (number of new cases per year) of leukemias differs from the prevalence (total 
cases of disease), where CLL is the most prevalent, but AML is the most incident. Although 
leukemia occurs more often in older adults, ALL is the most common form of cancer in 
children and adolescents. 
 
The Genetic Basis of Human Leukemia 
 
Leukemogenic processes are generally induced by multiple genetic changes including 
chromosomal translocations, mutations, and deletions [109,108]. T-cell acute 
lymphoblastic leukemia (T-ALL) is typically characterized by constitutive activation of 
NOTCH1 signaling accompanied by deletions of the tumor suppressor genes p16/INK4A 
and p14/ARF in more than 70% of cases (Table 1). This activation of NOTCH1 is a result 
of mutations in the NOTCH1 gene, involving the extracellular heterodimerization and/or 
the C-terminal PEST domains [128], and about 15% of cases are associated with FBXW7 
mutations that reduce the degradation of activated NOTCH1 [84,121]. Additionally, 
aberrant expression of certain transcription factor genes, such as TAL1/SCL, TAL2, LYL1, 
BHLHB1, MYC, LMO1, and LMO2, contribute to T-ALL pathogenesis (Table 1) [123]. 
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These transcription factors are normally quiescent during T cell development, but become 
aberrantly activated during T-ALL pathogenesis. Their aberrant expression results from 
either recurrent chromosomal translocations or, in some cases, mutations affecting 
upstream regulatory pathways that can inactivate transcriptional repressor networks or 
induce aberrant transcriptional activation. B-cell acute lymphoblastic leukemia (B-ALL) is 
characterized by aneuploidy or gross chromosomal rearrangements in approximately 75% 
of cases (Table 1). Chromosomal rearrangements affecting genes related to hematopoiesis, 
tumor control, and tyrosine kinase activity are common and in combination with further 
genetic aberrations such as tumor suppressor inactivation and aberrant oncogene activation, 
lead to the leukemic phenotype [78]. 
AML is a genetically complex disease that has historically been sub-classified 
based on both large-scale cytogenetic and individual gene abnormalities [72]. Knowledge 
of the mutational status of the FLT3, NPM1, CEBPA, and KIT genes is helping to refine 
treatment protocols; whereas other mutations—including DNMT3A, IDH1/2, and TET2—
are expected to improve future prognostic predictions (Table 1) [24]. Though the biological 
functions of many AML-related genes have been detailed [72], determining driver vs. 
passenger mutations remains an ongoing effort. To better define clinically-relevant patient 
populations, it will be essential to further characterize the genetic abnormalities involved 
in AML and to distinguish coincident alterations from pathogenic driver mutations. 
 CLL is a leukemia subtype with great genetic heterogeneity, where any given 
mutation prevails in only 10-15% of cases (Table 1). However, CLL-associated gene 
mutations affect distinct pathways including those of NOTCH signaling, mRNA splicing, 
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processing and transport, and the DNA damage response (Table 1) [73]. Despite the 
quantity of genetic mutations in CLL, their contributing roles in disease initiation and 
progression remain elusive. For instance, Quesada et al. (2012) define 78 recurrently 
mutated CLL genes, with particular focus on the splicing factor SF3B1 [95]. As in T-ALL, 
NOTCH1 mutations are found in CLL, but it remains unclear whether these mutations drive 
leukemogenesis. Larger sample sizes may facilitate the detection of putative driver 
mutations affecting yet smaller patient subsets (2-5% of cases) [62]. The genetic 
heterogeneity in CLL has led to the investigation of numerous candidate genes and a 
handful of commonly affected pathways. 
Unlike CLL, more than 90% of CML cases are caused by a unifying genetic 
abnormality known as the Philadelphia chromosome, a specific chromosomal translocation 
between the long arms of chromosomes 9 & 22: t(9;22)(q34;q11) (Table 1) [106]. This 
translocation causes the expression and constitutive action of the oncogenic tyrosine kinase 
BCR-ABL1 [37]. The most common BCR-ABL1 fusion protein—p210BCR-ABL—results 
from translocation within the break point cluster region (BCR) between exons 12 and 16 
on chromosome 22 (Table 1). This fusion protein activates a number of downstream 
signaling pathways including: a) RAS-MAPK signaling that transcriptionally upregulates 
BCL-2; b) AKT signaling that stabilizes MYC and thus increases transcriptional activation 
of MYC downstream targets; and c) STAT5 signaling that leads to the transcription of 
BCL-xL [96]. Although targeting the BCR-ABL1 fusion protein with the tyrosine kinase 
inhibitor Imatinib is an effective therapeutic strategy for the management of CML during 
the chronic phase, the disease remains incurable upon progression [8].
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Table 1: Summary of genetic alterations in human ALL, AML, CLL, and CML 
    Disease Gene Activation, Fusion, Inactivation 
or Mutations 
Translocations Deletions 
 
     ALL 
 
RB1, WT1, GATA3, CCND2, ETV6, RUNX1, EZH2, 
SUZ12, EED, PHF6, NOTCH1, FBXW7, PTEN, 
NRAS, NF1, JAK1, JAK3, FLT3, IL7R, CDKN2A/2B, 
BCL11B, LEF1, MYC, CDKN1B, NUP214-ABL1, 
TEL-AML1, EML1-ABL1, ETV6-ABL1, ETV6-JAK2, BCR-
ABL1 
 
 
t(14;21)(q11.2;q22) 
t(11;14)(p13;q11) 
t(1;14)(p32;q11) 
t(1;7)(p32;q34) 
t(7;7)(p15;q34) 
t(10;11)(p13;q14) 
t(11;19)(q23;p13) 
t(7;14)(q34;q13) 
t(14;20)(q11;p11) 
t(6;7)(q23;q34) 
t(7;19)(q34;p13) 
t(7;11)(q34;p15) 
t(7;12)(q34;p12) 
t(11;14)(p15;q11) 
t(7;9)(q34;q32)  
t(7;11)(q34;p13) 
inv(7)(p15q34) 
inv(14)(q11.2q13) 
inv(14)(q13q32.33) 
 
 
del(1p32) 
del(11p13) 
del(9q34) 
del(9p21) 
 
     AML 
 
IDH2, NRAS, TP53, KRAS, RUNX1, NPM1, FLT3, 
DNMT3A, IDH1, TET2, CEBPA, WT1, PTPN11, 
KIT, MYST3-NCOA2, AML1-ETO, NUP98-HOXA9 
 
t(15;17) 
t(8;21)(q22;q22) 
inv(16)(11q23) 
inv(8)(p11q13) 
 
del(5q) 
del(7q) 
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     CLL ZMYM3, CHD2, SF3B1, U2AF2, SFRS1, XPO1,  
ATM, TP53, LRP1B, MAPK1, MYD88, IGHV, 
NOTCH1, FBXW7, DDX3X, TLR2, POT1  
 
t(14;18)(q32;q21)  
t(14;19)(q32;q13)  
t(11;14)(q13;q32)  
t(17;18)(p11;q11) 
 
del(11q22-23)  
del(17p13) 
del(13q14)  
 
     CML 
 
BCR-ABL1, EVI1, RB1, TP53, CDKN2A,  
ETV6-JAK2 
 
t(9;22)(q34;q11) 
inv(3)(q21q26) 
t(3;21)(q26;q22) 
t(15;17)(q22;q12-21) 
 
 
IKZF1 Δ3–6 
Information summarized from Van Vlierberghe, Ferrando [123],Takeuchi et al. [117] (ALL); Cancer Genome Atlas Research [18] 
(AML); Wang et al. [125],Martin-Subero et al. [73],Baliakas et al. [5] (CLL); Johansson et al. [56],Rumpold, Webersinke 
[103],Mullighan et al. [79] (CML).
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Remaining Challenges in Leukemia Treatment 
 
Intensification of standard therapeutic agents has improved clinical outcomes in many 
leukemia subtypes. However, five-year survival rates for leukemia remain low: 68.8% for 
ALL, 24.9% for AML, 83.1% for CLL, and 58.6% for CML [17]. Among adult patients, 
only 20 to 30% with ALL and 30 to 35% (younger than 60 years) with AML achieve 
complete remission and are considered cured [109,108].  These high mortalities are resulted 
from induction failure, disease progression and relapse, and toxicities associated with 
current treatment protocols [50]. For instance, patients with acute leukemia face an 
extremely poor five-year survival rate (~10%) after disease relapse, where treatment 
intensification often increases toxicity without improving outcome [1]. Direct and indirect 
toxicological complications include anthracycline-related cardiotoxicities, hepatotoxicity, 
peripheral neuropathy, central neurotoxicity, nephrotoxicity, cutaneous toxicity, 
myelosuppression—leading to anemia, thrombocytopenia, neutropenia, and infection—
capillary leak syndrome, cytokine release syndrome, hypogammaglobulinemia, graft-
versus-host disease, and veno-occlusive disease [1,4,15,75,99]. The need for more 
tolerable and targeted therapies is clear. 
 The development of monoclonal antibodies, immunotherapies, cancer vaccines, 
and improvements in hematopoietic stem cell transplantation (HSCT) are contributing to 
more effective management and treatment of human leukemia. Antibody therapies are 
generally more tolerable than traditional chemotherapeutics and remain an area of 
developmental focus, despite limited monotherapeutic efficacy [127]. Very recently, the 
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bi-specific T-cell engager monoclonal antibody blinatumomab received approval from the 
U.S Food and Drug Administration. Other antibody therapeutics in clinical trials include 
traditional naked antibodies, immunoconjugates, and immunotoxins [1]. As compared to 
traditional small molecule drugs, these next-generation antibody therapeutics are more 
specific for and cytotoxic against cancer cells [127]. 
Immune-based strategies for leukemia treatment represent another area of rising 
research interest. Cancer vaccines and immunotherapies are in clinical testing and provide 
potential means of reducing relapse following chemotherapy and HSCT [16,50]. Small 
clinical trials for ALL and CLL have demonstrated that patients’ own T cells can be 
genetically engineered (e.g. chimeric antigen receptor-modified T cells) to potently 
eradicate cancer cells through the targeting of tumor antigens [19,16,90]. Drugs that modify 
cancer-related immunosuppression or enhance innate immunity are likely to improve the 
efficacy and durability of future treatment protocols [17]. 
These advances,as both monotherapies and potentially in combination with current 
standard protocols, promise to significantly advance the treatment of leukemia. To exploit 
this potential, research to identify and develop biomarkers that can predict drug efficacy in 
individual patients is necessary [20]. Predictive biomarkers could be of value for assessing 
immunotherapies, particularly for cancer vaccination, where discordant patterns of 
antibody responses arise from even identical treatments [94]. Unsurprisingly, even targeted 
therapies are not completely effective and are complicated by therapeutic resistance, 
characterized by the expansion of cancer clones lacking the molecule targeted by therapy 
[1]. Therefore, in vivo research with animal models of human leukemia will allow better 
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understanding of the pathologies of treatment resistance, advanced disease, treatment 
toxicities, and immunopathologies. 
 
2. Conservation of Zebrafish Hematopoietic Program  
 
The zebrafish (Danio rerio) is a freshwater fish with characteristics including high 
fecundity, rapid development, transparency, and closer homology to humans than that of 
invertebrates. Zebrafish hematopoiesis is highly conserved, well suited to the study of 
normal hematopoiesis and malignant transformation [29,70,30]. As in mammals, zebrafish 
blood cellular components are produced and replenished by distinct yet overlapping waves 
of primitive and definitive hematopoiesis [29,7,35]. Beginning 12 hours post-fertilization 
(hpf), primitive erythropoiesis occurs in the intermediate cell mass and myelopoiesis 
initiates in the anterior lateral mesoderm. Definitive hematopoiesis initiates around 26 hpf 
when hemogenic endothelial cells give rise to hematopoietic stem cells (HSCs) in the 
ventral wall of the dorsal aorta, a structure within the aorta-gonad-mesonephros [6,59]. 
These HSCs then migrate to secondary hematopoietic compartments: the caudal 
hematopoietic tissue (an intermediate site of hematopoiesis that is comparable to the liver 
of mammals), the thymus (an organ where T lymphocytes mature), and the kidney marrow 
(equivalent to the bone marrow of mammals). HSCs in the kidney subsequently give rise 
to all hematopoietic lineages—erythroid, myeloid, and lymphoid—throughout the life of 
the fish (Figure 1). 
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Figure 1: Schematic overview of zebrafish definitive hematopoiesis 
 
Green paths indicate the myeloid lineage and blue paths indicate the lymphoid lineage. 
Transcription factors implicated in hematopoiesis are shown next to each cell type and those 
associated with mutations, chromosomal abnormalities, or misexpression in leukemia are shown in 
red. Granulocyte/macrophage progenitors (GMP); hematopoietic stem cells (HSC); lymphoid 
progenitor cells (LP); megakaryocyte-erythrocyte progenitors (MEP); myeloid progenitor cells 
(MP); pro-B-lymphocytes (Pro-B); and pro-T-lymphocytes (Pro-T). 
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 Since 1963 and especially during the past two decades [25], significant knowledge 
of the molecular mechanisms underlying blood cell development has been collected 
through investigations of gene inactivation and/or heritable mutations in zebrafish [87,21]. 
Indeed, the genetic programs governing zebrafish blood cell development are highly 
conserved. Critical transcription factors such as Gata2, Scl (Tal1), Lmo2, Myb, and Runx1 
control the self-renewal and differentiation of HSCs in zebrafish and mammals alike 
(Figure 1) [87,136]. Similarly, progenitor cell development is finely tuned by the 
expression of a number of specific transcription factors and regulators. For instance, the 
expression of pu.1 (spi1) and cebp 1 control the fate of granulocyte/macrophage 
progenitors (GMP) (Figure 1) [51,100,28]. The transient expression of Rag1 and Rag2 
recombinases promotes the maturation of T and B lymphocytes (Figure 1) [85]. To ensure 
proper blood cell development the expression of these genes must be tightly regulated, as 
their aberrant expression often leads to differentiation arrest and malignant transformation. 
Following elucidation of these blood cell regulators, their promoter regions were 
isolated and characterized, allowing the generation of transgenic zebrafish lines expressing 
fluorescent reporter genes and oncogenes implicated in hematopoietic malignancy. The use 
of multiple transgenic fluorescent reporter systems (e.g. green fluorescent protein [GFP], 
enhanced GFP [EGFP], and red fluorescent protein [RFP]) has facilitated the visualization 
and study of specific cell lineages and the monitoring of leukemic initiation and 
progression in living fish [35,21]. To date, transgenic lines of all three hematopoietic 
lineages have been generated: a) gata1:dsRed2 for erythrocytes [132]; b) pu.1:GFP for 
myeloid progenitor cells [100], mpo:GFP for neutrophils [74], lyzC:dsRed2 and 
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mpeg:GFP for macrophages [36]; and c) lck:EGFP for T-lineage only [64], and rag1:GFP 
and rag2:GFP for both B and T cells [55,54]. Additionally, the availability of CD41:GFP 
transgenic fish has facilitated the isolation of HSCs based on GFP intensity [69,71]; low 
GFP intensity identifies HSCs, whereas high or medium intensity identifies thrombocytes. 
In summary, investigation of these transgenic and mutant fish led to important insights into 
normal hematopoiesis and malignant transformation (detailed in Section 4). 
 
3. Technological Advances Enabling the Experimental Tractability of Zebrafish 
 
Over the past decade researchers have developed and optimized multiple methodologies 
for the zebrafish, today they are particularly amenable to experimental manipulation. 
Improvements in transgenesis have enabled the misexpression of various oncogenes in all 
blood lineages, while ongoing efforts within the zebrafish community have continued to 
generate a large collection of mutants. These mutants facilitate the use of forward genetic 
screens to identify mutations modifying the leukemic phenotype. The ability to precisely 
edit the zebrafish genome has driven the study of tumor suppressor inactivation in 
leukemogenesis. Finally, the transparency and optical clarity of zebrafish embryos and an 
adult strain known as Casper—so called because of its ghost-like appearance—have made 
it feasible to track the behavior of leukemic cells in real time at single-cell resolution and 
without surgical intervention [130]. 
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Transgenesis and Mutagenesis 
 
The application of meganuclease I-SceI- or Tol2-mediated transgenesis has been shown to 
significantly improve rates of germ-line integration over conventional transgenesis with 
linear-DNA injection (16-50% vs. 1-5%) [58,120].  The ability to efficiently generate 
transgenic zebrafish in the injected (F0) generation represents a major advantage over other 
animal models, where the generation of stable transgenic animals typically requires several 
generations before these new lines can be used experimentally. The development of 
conditional transgenesis (e.g. Cre/lox-regulated, tamoxifen-regulated, GAL4-UAS-
regulated, and tetracycline-inducible systems) has provided further capability in enabling 
the expression of oncogenes and tumor suppressors with spatial and temporal specificity 
[45,63,107,138]. Moreover, the ability to deliver two to three transgenic constructs into the 
same cell through co-injection is particularly useful. Co-injection facilitates the 
identification of transgenic fish by the activity of a fluorescent reporter construct alongside 
the transgene of interest, enabling the selection of fish with positive transgene expression 
[97]. Additionally, the co-expression of multiple transgenes of interest in the same cells 
enables the dissection of multiple genetic pathways in the leukemic context [65,97]. These 
improvements in transgenic techniques have led to the generation of various zebrafish 
leukemia models and functional studies of candidate leukemogenic genes (detailed in 
Section 4). 
While zebrafish transgenesis enables the misexpression of exogenous genes in a 
specific cell lineage, mutagenesis can effect enhanced expression, dominant-negative 
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effects, and/or the inactivation of an endogenous gene throughout the entire organism. 
Incorporating UV irradiation, chemicals (e.g. N-ethyl-N-nitrosourea [ENU]), viruses, and 
transposons (e.g. Tol2) as mutagens, high-throughput mutagenesis projects have generated 
a large collection of zebrafish mutants over the past two decades, including blood mutants 
[3,80]. These mutant fish represent a rich resource for investigators working to identify 
mutations capable of modifying leukemia onset and progression. A recent genetic 
suppressor screen utilizing a collection of insertional mutants led to the identification of 
dihydrolipoamide S-succinyltransferase as an important contributor to Myc-induced T-
ALL pathogenesis (Anderson and Feng; personal communications, 2015). Targeting 
Induced Local Lesions in Genomes (TILLING) combines the use of a chemical mutagen 
(e.g. ENU) with a single-base-mutation screening technique. With advances in whole-
genome sequencing, TILLING-by-sequencing (Illumina) has been developed to rapidly 
identify single-nucleotide changes and significantly speed the screening process. This 
technique has led to the identification of multiple mutants affecting blood development, 
including the rag1R797stop and pu.1G242D mutants (Figure 1) [116,131]. The rag1R797stop 
mutant is defective in V(D)J recombination and fails to generate mature T and B cells 
[131]. The pu.1 G242D mutant results in reduced Pu.1 activity and increased granulocytes 
with patterns comparable to human AML [116]. 
 
  
 14 
Gene Inactivation and Genome Editing 
 
Gene inactivation is the preferred method for the functional study of tumor suppressors in 
the leukemic context. Although antisense morpholino oligonucleotides have been used for 
gene knockdown in zebrafish, they are susceptible to undesirable off-target effects and 
their transience is inapplicable to studies in larval or adult fish [67]. Small hairpin RNA 
gene inactivation is effective in embryos [31]; however, its feasibility in adult fish remains 
to be proven. The zebrafish community has successfully developed multiple genome 
editing techniques, including zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and clustered regularly interspaced short palindromic 
repeats/CRISPR associated (CRISPR/Cas9) technologies, enabling site-directed 
mutagenesis and precise single-base genome editing [105,53,33]. The Langenau group 
successfully applied TALENs, generating rag2E450fs mutants with reduced numbers of 
mature T and B cells [118,119]. Both rag1R797stop and rag2E450fs mutant fish are 
immunocompromised and provide excellent tools for the long-term engraftment of various 
tissues and leukemic cells [118,131]. With efficiencies comparable to ZFNs and TALENs, 
the CRISPR/Cas9 system provides a simple, rapid, and adaptable method to generate loss-
of-function alleles by targeting open reading frames [53]. Because leukemia is a 
heterogeneous disease, often involving the simultaneous misexpression of oncogenes and 
the inactivation of tumor suppressors, the ability to genetically manipulate the zebrafish 
genome easily and precisely makes zebrafish particularly well suited for modeling human 
leukemia. 
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Improved Imaging Techniques 
 
Given the optical clarity of embryos and the transparency of adult Casper fish, the zebrafish 
is an excellent model for tracking the movement of normal or malignant blood cells with 
live-cell imaging [77]. The fluorochrome labeling of each blood cell lineage enables 
researchers to monitor leukemic initiation, dissemination, and regression with a fluorescent 
microscope in real time. The most commonly used fluorochrome is GFP, though blue 
fluorescent protein (e.g., lyn-Cyan), zsYellow, mCherry, and dsRed2 are available as well. 
To track fluorescent tumor cells, researchers fuse GFP or EGFP to an oncoprotein of 
choice; examples include EGFP-mMYC [66], EGFP-TEL-AML1 [104], EGFP-ICN1 [23], 
and MYST3/NCOA2-EGFP [139]. However, this strategy is limited by the fact that in 
some cases fast degradation of the oncogene can weaken the GFP signal. Additionally, the 
fluorochrome tag may adversely affect oncogene functionality and/or subcellular 
localization [77]. To avoid these pitfalls, co-injection is used to independently drive the 
expression of both the oncogene and the fluorescent protein with separate transgenic 
constructs inside the same cells [65,97]. 
Stereomicroscopy is broadly applied for the imaging and dissection of fluorescently 
labeled tissues in zebrafish. However, stereomicroscopes are limited to imaging one fish at 
a time. Moreover, acquire an image of the entire adult fish, even at low magnification, can 
be difficult. To facilitate the high-throughput screening and scoring of zebrafish, the 
Langenau group developed a light emitting diode (LED) fluorescent macroscope system 
[9,112]. This LED fluorescent macroscope is cost effective and capable of simultaneously 
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imaging up to 30 fish in a single petri dish. Additionally, LED macroscopy can differentiate 
five different fluorochromes and is suited to real-time imaging and time-lapse video 
recording of live zebrafish. A drawback of LED macroscopy is its reduced sensitivity, 
which limits detailed imaging of small tumors and single circulating cells. 
Laser scanning confocal microscopy (LSCM) is a powerful technology with 
increased optical resolution and contrast. Laser light is focused on a single point within a 
defined focal plane, eliminating noise from other planes and reducing image distortions. 
Fluorescent scanning of multiple focal planes can be reconstructed as a z-series and 
mapped in three dimensions onto a zebrafish anatomical atlas. Sabaawy et al. used LSCM 
to image EGFP-TEL1-RUNX1 expression in adult fish [104]. Zhang et al. demonstrated 
the ability to track and count circulating blood cells in adult zebrafish via the combination 
of LSCM and in vivo flow cytometry [137]. The disadvantage of LSCM scanning is its rate 
of acquisition (each pixel is acquired individually) and its high levels of laser exposure, 
which can result in photobleaching and phototoxicity. Spinning disc confocal microscopy 
(SDCM) utilizes a disc with different pinhole apertures; this technique captures multiple 
pixels simultaneously, thereby shortening acquisition time. Although SDCM resolution is 
less than that achieved with LSCM, imaging is significantly faster and more protective 
against phototoxicity. 
 Overall, significant progress has been made to improve the tractability of 
zebrafish for the modeling and mechanistic elucidation of leukemogenesis. With the 
increasing sophistication and availability of genetic techniques and imaging tools, 
zebrafish have proven complementary to both murine models and cell culture systems. 
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4. Leukemia Modeling and Mechanistic Insights 
 
As previously described, zebrafish have unique advantages that make them especially 
suited to the investigation of hematopoietic malignancies. To date, investigators have 
generated zebrafish models of T-ALL, B-ALL, and AML that can be experimentally 
manipulated to elucidate both the molecular and genetic components of leukemic 
transformation, progression, and maintenance. 
 
A. Disease Modeling  
 
T-ALL 
 
Multiple zebrafish T-ALL models have been generated during the past twelve years. The 
first model was developed via transgenesis in the Look laboratory. In this T-ALL model, 
the murine c-Myc gene (mMyc) was fused to EGFP to drive the expression of the EGFP-
mMyc fusion protein under the lymphocyte-specific rag2 promoter (Tables 1 and 2) [66]. 
This model provides the capacity to monitor the dissemination of tumor cells in a live 
vertebrate organism under a fluorescent microscope. However, high mortality rates among 
these heavily diseased leukemic fish preclude their fecundity. To overcome this, Langenau 
et al. (2005) developed a Cre/lox-regulated conditional system in which EGFP-mMyc 
expression is controlled by Cre-mediated recombination of the loxP-dsRed2-loxP cassette 
upon Cre mRNA injection (Table 2) [63]. This technique allows the maintenance of tumor-
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free rag2:loxP-dsRed2-loxP-EGFP-mMyc transgenic fish in the absence of Cre 
expression. 
This conditional T-ALL model was further improved by outbreeding it with 
hsp70:Cre transgenic fish, generating rag2:loxP-dsRed2-loxP-EGFP-mMyc;hsp70:Cre 
double-transgenic fish (Figure 2) [38]. Following heat-shock treatment at 3 days post 
fertilization (dpf), T-ALL developed in over 81% of double-transgenic fish around 120 
dpf. In addition to this Cre/lox-regulated conditional T-ALL model, Gutierrez et al.  (2011) 
developed a tamoxifen-regulated zebrafish model of T-ALL [45]. In this model, 4-
hydroxytamoxifen (4HT) treatment induces human MYC activation and T-ALL 
development in lymphocytes, and withdrawal of 4HT results in apoptosis and tumor 
regression (Figure 3A, C). In addition to these MYC-induced T-ALL models, Chen et al. 
(2007) developed a zebrafish model of T-ALL by overexpressing the intracellular portion 
of human NOTCH1 (ICN1) under the rag2 promoter (Table 2) [23]. Constitutive murine 
Akt2 activation in lymphocytes also promotes T-ALL development with low penetrance in 
zebrafish (Table 2) [45]. In addition to the transgenic T-ALL models mentioned above, 
Frazer et al. (2009) used ENU-mediated mutagenesis to identify three mutants—hrk, slk, 
and otg—to develop genetically heritable T-ALL in the background of lck:EGFP 
transgenic fish [42] (Table 2). The gene identity of these mutations is currently under 
investigation. 
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Figure 2: The Cre/lox-regulated T-ALL model in zebrafish 
 
(A) Schematic of the hsp70:Cre and rag2:loxP-dsRed2-loxP-EGFP-mMyc constructs. (B-G) 
Overlay of brightfield and fluorescence image of T cells expressing either dsRed2 and/or EGFP-
mMyc shows T-LBL/T-ALL development in double transgenic rag2:loxP-dsRed2-loxP-EGFP-
mMyc;hsp70:Cre fish, with no (red only) or incomplete (red + green) excision of loxP-dsRed2-
loxP cassettes. (A–G) (Republished with permission from John Wiley and Sons) [38]. 
 
B-ALL 
 
Modeling B-ALL in zebrafish has proven challenging. Mysteriously, oncogene 
overexpression driven by the rag2 promoter only leads to T-ALL development, despite 
oncogene expression in both T and B cell lineages [38,45,63,66,23]. Despite multiple 
attempts in different laboratories using various oncogenes and promoters, the only 
zebrafish model of B-ALL is generated by overexpressing the TEL-AML1 fusion gene 
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under ubiquitous promoters. The t(12, 21)(p13;q22) TEL-AML1 (ETV6-RUNX1) 
chromosomal translocation is the most common genetic rearrangement in childhood 
cancer, presenting in 25% of pediatric pre-B ALL (Table 1) [92]. Sabaawy et al. (2006) 
overexpressed the human TEL-AML1 gene under the elongation factor, β-actin, or rag2 
promoters in an attempt to determine the cellular origin and molecular pathogenesis of 
TEL-AML1-induced B-ALL (Table 2) [104]. Interestingly, B-ALL arises in transgenic fish 
only when TEL-AML1 is expressed under ubiquitous promoters, but not when expressed 
under the lymphocyte-specific rag2 promoter. Leukemia development in these fish is 
associated with B cell differentiation arrest, loss of TEL expression, and an elevated Bcl-
2/Bax ratio. Long disease latency (8-12 months) and low tumor penetrance (3%) in this 
model indicate the necessity of compound genetic alterations for B cell transformation. 
Thus, TEL-AML1 transgenic fish are useful for genetic screens to identify cooperating 
mutations that may accelerate B-ALL development in the context of TEL-AML1 
expression. 
 
AML and Other Myeloid Malignancies 
 
The only AML model currently available was developed by the Delva group and is based 
on AML’s association with the inv(8)(p11q13) chromosomal abnormality (Tables 1 and 2) 
[139]. This chromosomal translocation fuses two histone acetyltransferase genes—MYST3 
and NCOA2. Expression of the MYST3-NCOA2 fusion gene under the pu.1 (spi1) promoter 
led to AML development in 2 of 180 F0 mosaic fish at 14 and 26 months of life, 
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respectively, with characteristics including an extensive invasion of myeloid blasts in the 
kidney. This study demonstrated the oncogenic potential of the MYST3-NCOA2 fusion 
gene resulting from the inv(8)(p11q13) chromosomal abnormality within an in vivo animal 
model. 
In addition to the AML model described above, a number of transgenic zebrafish 
lines have been generated via the exploitation of additional genetic abnormalities in AML. 
Interestingly, instead of developing AML, these transgenic lines have developed 
myeloproliferative neoplasm (MPN) or myelodysplastic syndrome (MDS), malignancies 
with potential to progress to AML.  The Look laboratory recently generated an MDS fish 
model through inactivation of the tumor suppressor Tet2 via TALENs [43]. TET2 encodes 
a DNA methylcytosine oxidase that is essential for demethylating DNA within genomic 
CpG islands [49]. TET2 loss-of-function mutations were found in multiple myeloid 
malignancies, including MDS, MPN, AML, and CML (Table 1) [81]. Notably, 
hematopoiesis in tet2 homozygous mutants is normal throughout embryogenesis and larval 
development, whereas progressive clonal myelodysplasia arises in aged adult fish. 
One example of modeling MPN is the AML1-ETO transgenic fish generated by the 
Peterson group (Table 2) [133]. The AML1-ETO fusion protein results from the 
t(8;21)(q22;q22) chromosomal translocation in AML (Table 1). Patients expressing the 
AML1-ETO fusion gene exhibit an accumulation of granulocytic precursors in the bone 
marrow and peripheral blood [32]. Similarly, expressing the human AML1-ETO gene under 
the hsp70 promoter redirects myeloerythroid progenitor cells to the granulocytic cell fate, 
leading to the expansion of granulocyte precursors in transgenic AML1-ETO embryos. This 
 22 
change is accompanied by a loss of gata1 expression and an elevated pu.1 expression in 
myeloerythroid progenitor cells. This zebrafish model has been used to discover AML1-
ETO-induced oncogenic signaling and to screen for compounds that exert anti-leukemic 
effects (see Section 6).  
An MPN model in NUP98-HOXA9 transgenic fish was developed in the Berman 
laboratory [41]. The NUP98-HOXA9 fusion protein is formed by translation of the 5’ 
region of nucleoporin 98 kDa (NUP98) on human chromosome 11 in frame to the 3’ coding 
sequence of homeobox A9 (HOXA9) on human chromosome 7 (Table 1) [14,41]. Forrester 
et al. (2011) utilized Cre/lox recombination to conditionally express the human NUP98-
HOXA9 gene under the pu.1 promoter (Table 2) [41]. Their study demonstrated that 
NUP98-HOXA9 expression impaired hematopoiesis, leading to an expansion of myeloid 
precursors [41].  Within 19 to 23 months, 23% of fish developed MPN. The NUP98-
HOXA9 transgenic fish represents yet another tool for drug discovery and investigation of 
the pathogenesis of MPN. See Table 2 for details on other zebrafish MPN models 
[116,68,2,111].
  
2
3
 
Table 2: Summary of zebrafish models of leukemia 
Tumor Method 
Transgenes 
or genes disrupted 
Earliest 
disease 
onset 
Characteristics/application References 
T-ALL Stable 
transgenesis 
rag2:EGFP-mMyc 22 days The first zebrafish model of 
leukemia  
[66]  
T-ALL Cre/lox-
regulated 
rag2:loxP-dsRed2-loxP-EGFP-mMyc 
Cre mRNA injection 
4 months Similar to human T-ALL 
subtype with SCL and 
LMO2/LMO1 activation 
[63] 
T-ALL Cre/lox-
regulated 
 
rag2:loxP-dsRed2-loxP-EGFP-
mMyc;hsp70:Cre 
2 months Heat-shock inducible; 
Elucidation of genetic basis 
of T-LBL dissemination to 
T-ALL; 
Determined the effect of p53 
inactivation on Myc-induced 
T-ALL onset 
[38,39,44] 
T-ALL Tamoxifen-
regulated 
rag2:MYC-ER;mitfa 4 weeks Mechanistic dissection of 
MYC-PTEN-AKT-BIM 
regulation; 
Small molecule screens to 
identify perphenazine with 
anti-leukemic activity 
[45,98,44] 
T-ALL Stable 
transgenesis 
rag2:EGFP-ICN1 
 
 
5 months Demonstrated the effect of 
bcl-2 to accelerate ICN1-
induced T-ALL onset. 
[23] 
T-ALL Transient 
transgenesis 
rag2:Myr-Akt2 6 weeks Determined the role of Akt2 
in T-ALL maintenance and 
progression 
[39,45] 
  
2
4
 
T-ALL Random 
ENU-
mediated 
mutagenesi
s 
srk 
hlk 
otg 
3-6 
months 
Discovery of potential new 
genetic players for T-ALL 
[42] 
B-ALL Stable 
transgenesis 
-actin:EGFP-TEL-AML1 
ef1:EGFP-TEL-AML1 
  8 months The first B-ALL model 
in zebrafish; Provided a tool 
for enhancer screens 
[104] 
AML Stable 
transgenesis 
pu.1:MYST3-NCOA2-EGFP 14 months Demonstrated the oncogenic 
potential of the MYST3-
NCOA2 fusion protein in 
vivo 
[139] 
MPN Cre/lox-
regulated 
-actin:loxP-dsRed2-loxP-
KRASG12D; 
hsp70-Cre 
3-6 
months 
The first zebrafish MPN 
model; 
Studied the role of 
MAP/ERK pathway in MPN 
[68] 
MPN Stable 
transgenesis 
hsp70:AML1-ETO 1-dpf 
embryos 
Expanded myelopoiesis in 
embryos with gene 
expression resembling 
human AML; 
Small molecule screens to 
identify the Cox1 inhibitor 
[133,134] 
MPN Cre/lox-
regulated 
pu.1:loxP-EGFP-loxP-NUP98-
HOXA9; 
hsp70-Cre 
19-23 
months 
Zebrafish MPN model 
induced by NUP98-HOXA9; 
Applicable for small 
molecule screens 
[41] 
MPN GAL4-
UAS-
regulated 
fli1:GAL4-FF; 
UAS-GFP-HRASG12V 
embryos Discovery of repression of 
NOTCH signaling by RAS 
expression 
[2] 
  
2
5
 
MPN Transient 
mRNA 
injection 
Cytoplasmic NPM1 mutant embryos Increased primitive myeloid 
cells  
[12] 
MPN Transient 
expression 
of mRNA 
RUNX1-CBF2T1 embryos Perturbation of normal 
hematopoiesis 
[57] 
MPN Heat-shock 
inducible 
Stable 
transgenesis 
EGFP:HSE:mMycN 2 months Myeloid blasts infiltration in 
zebrafish organs 
[111] 
MDS TALENs tet-2 inactivation 11 months Utilized genome editing 
technology to generate a 
MDS model in zebrafish 
[43] 
MDS TILLING pu.1G242D 18 months Expanded myelopoiesis; 
Tested current standard 
therapeutics on these fish 
[116] 
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B. Mechanistic Insights 
 
The availability of these models has allowed investigators to study the genetic basis of 
leukemia, from disease initiation to progression and drug resistance. Importantly, the 
molecular mechanisms underlying zebrafish leukemogenesis are strikingly similar to those 
in humans, providing a unique opportunity to utilize the imaging and genetic advantages 
intrinsic to zebrafish for continued insight into human disease. In this subsection advances 
made by investigations of zebrafish leukemia models in conjunction with other 
experimental systems are discussed. 
 
Genetic Similarities Between Human Disease and Zebrafish Models of Leukemia  
 
As studies using genome-wide approaches in zebrafish models emerged it became clear 
that gene expression signatures and genetic alterations in zebrafish models of leukemia are 
comparable to those in humans. Langenau et al. (2005) analyzed Myc-induced T-ALL cells 
in zebrafish and found that these cells upregulate scl and lmo2 oncogenes, resembling a 
major subtype of human T-ALL [40,63]. Rudner et al. (2011) performed comparative 
genomic hybridization with Myc-induced zebrafish T-ALL cells obtained from 
transplanted fish, aiming to identify the recurrent genomic changes underlying disease 
relapse [102]. When zebrafish data were compared to a cohort of 75 published human T-
ALL databases, 893 genes (67%) were found to overlap between fish and human T-ALL. 
Blackburn et al. (2012) performed gene expression profiling analysis on zebrafish T-ALL 
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cells induced by activated Notch1 signaling [10]. A cross-comparison between zebrafish 
and human T-ALL microarray data revealed a conserved T-ALL signature shared between 
fish and human leukemia. Together, these studies support that zebrafish and human 
leukemia—particularly T-ALL—are driven and controlled by shared oncogenic pathways. 
 
The NOTCH-MYC Axis 
  
The NOTCH signaling pathway plays an indispensable role in hematopoiesis and T cell 
development [124]. Activating NOTCH1 mutations were discovered in both human and 
murine T-ALL samples [83,128]. In zebrafish, overexpression of human ICN1 in the 
lymphocyte lineage leads to the activation of NOTCH1 downstream genes (e.g., her6 and 
her9) and T-ALL development [23]. Long latency and low penetrance of tumor 
development in this model indicates the requirement of additional cooperating mutations 
for leukemic transformation together with the activated NOTCH1 signaling. The 
oncogenic role of MYC in the lymphoid lineage was first suggested by clinical observation 
of the translocation of MYC into the immunoglobulin heavy chain locus (E) in human 
Burkitt lymphoma cells [60,27]. Subsequently, researchers generated a transgenic E:Myc 
murine model in which B cell lymphoma rapidly arose, demonstrating MYC’s oncogenic 
effect in vivo [48]. In zebrafish, overexpression of the human MYC or murine Myc gene 
under the control of the rag2 promoter leads to the rapid development of T-ALL but not 
B-ALL (Table 2) [38,45,63,66]. This rapid MYC-driven T-ALL development was later 
connected to the activation of NOTCH1 signaling as MYC was identified to be a direct 
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transcriptional target of NOTCH1 in mammals [61,110,122,88,128,129]. These studies 
established the important role of NOTCH and MYC in T-ALL pathogenesis. As opposed 
to its effect in mammals, Notch activation in zebrafish does not transcriptionally induce 
myc, providing a unique system with which to study NOTCH or MYC signaling 
independently of one another [10]. 
 
The PTEN-PI3K-AKT Pathway 
 
Initial investigations of PTEN-PI3K-AKT signaling in T-ALL cells began after the 
discovery that NOTCH1 inhibition by -secretase is only sensitive in a subset of T-ALL 
cell lines [46]. Palomero et al. (2007) elucidated the mechanisms that confer the resistance 
of T-ALL cells to -secretase inhibition, leading to the discovery of NOTCH1’s regulation 
of PTEN expression [88]. Loss-of-function PTEN mutations confer the resistance of T-
ALL cells to the inhibition of NOTCH1 signaling due to activation of PI3K-AKT signaling. 
Gutierrez et al. (2011) employed their rag2:MYC-ER transgenic zebrafish to 
investigate genetic factors that are required for T-ALL maintenance [45].  In this model, 
tamoxifen treatment activates MYC signaling to encourage leukemogenesis. Subsequent 
removal of tamoxifen inactivates MYC, after which T-ALL cells undergo apoptosis rapidly 
in the absence of MYC (Figure 3A, C). Importantly, when pten loss-of-function mutations 
are introduced into these fish, T-ALL cells no longer undergo apoptosis; instead, the 
disease progresses independently of MYC activation (Figure 3B,D-E). This result can be 
explained by MYC’s ability to transcriptionally repress PTEN, so that PTEN upregulation 
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following MYC inactivation is a key mediator of T-ALL regression in this context. 
Notably, AKT pathway activation downstream of PTEN signaling is sufficient for 
leukemic maintenance and progression despite inactivation of the MYC transgene (Figure 
3F). This work highlights the importance of the PTEN-PI3K-AKT pathway in MYC-
independent disease maintenance and identifies mechanisms used by drug resistant T-ALL 
cells in the context of PTEN loss or AKT activation. 
 
Figure 3: pten haploinsufficiency promotes loss of MYC transgene dependence 
 
(A and C) One representative rag2:MYC-ER; rag2:GFP double-transgenic pten–wild-type 
zebrafish, shown at time of T-ALL onset (A) and 3 wk after removal from 4HT (C). (B and D) 
Representative rag2:MYC-ER; rag2:GFP double-transgenic zebrafish that harbored heterozygous 
mutations of both ptenA and ptenB, shown at time of T-ALL onset (B) and 3 wk after removal 
from 4HT (D). Bar, 1 mm. (E) Quantitation of T-ALL phenotypes after 4HT removal, based on 
pten genotype. Number of fish with T-ALL analyzed per genotype: ptenA +/+, ptenB +/+, n = 39; 
ptenA +/+, ptenB +/-, n = 12; ptenA +/-, ptenB +/+, n = 22; ptenA +/-, ptenB +/-, n = 10. (F) 
Western blot analysis for phosphorylation of S6 ribosomal protein, a marker of Akt pathway 
activation, in sorted T-ALL cells from five different rag2:MYC-ER pten–wild-type zebrafish in 
which T-ALL progressed despite MYC downregulation. Units for the molecular mass markers 
shown are in kD (republished with permission from The Rockefeller University Press) [45]. 
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Escape of Leukemia Cells from Apoptosis 
 
On the road to malignant transformation, cells must dampen the apoptotic response 
triggered by oncogenic stress.  Acquired mutations, chromosomal deletions, and gene 
transcriptional repression or overexpression are a few means that cancer cells utilize to 
escape apoptosis (Table 1) [93]. Decades ago, using the murine E:Myc model previously 
noted, researchers learned the importance of Bcl-2 overexpression and suppression of the 
Arf-P53 apoptotic pathway in Myc-mediated transformation [114,34]. As in mammals, 
bcl-2 overexpression in zebrafish dramatically accelerates Myc- or NOTCH1-induced 
tumor onset in the T cell lineage [39,23]. Moreover, in a zebrafish model of B-ALL, an 
elevated Bcl-2/Bax ratio was observed in B-ALL cells overexpressing the TEL-AML1 
fusion gene [104]. This evidence underscores the importance of apoptotic escape during 
zebrafish T and B cell transformation. Surprisingly, the zebrafish does not appear to have 
an arf locus as evidenced by a recent study demonstrating that P53 inactivation does not 
impact T-ALL onset [44]. 
Combining the analysis of a tamoxifen-regulated T-ALL model with human T-ALL 
cell lines, Reynolds et al. (2014) identified repressed expression of BIM (a pro-apoptotic 
BCL2 family member) in both human and zebrafish T-ALL cells, allowing them to escape 
apoptosis [98]. The repressed BIM expression is mediated by MYC overexpression; MYC 
downregulation upon tamoxifen removal restores bim expression in zebrafish T-ALL cells, 
promoting apoptosis and tumor regression in vivo.  Alternatively, AKT activation can lead 
to the suppression of BIM expression. When human T-ALL cells were treated with MYC 
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or PI3K-AKT pathway inhibitors, BIM expression was upregulated and subsequently 
promoted T-ALL cell apoptosis. These results indicate that identifying and restoring 
molecular mechanisms leukemic cells use to escape apoptosis (e.g. BIM-mediated 
apoptosis), represents a promising therapeutic approach. 
 
Genetic Basis of T-LBL Dissemination to T-ALL 
 
T-ALL and T-cell acute lymphoblastic lymphoma (T-LBL) have distinct clinical 
presentations. T-ALL is defined by a bone marrow biopsy with a composition of 30% T-
lymphoblasts, while T-LBL is defined by a mediastinal mass where 30% of blasts are in 
circulation. Feng et al. (2010) utilized a Cre/lox-regulated T-ALL model in combination 
with clinical patient sample analyses to investigate the molecular and cellular mechanisms 
underlying the progression of T-LBL to T-ALL (Figures 2 and 4) [38,39]. Interestingly, 
when bcl-2 was overexpressed in this Myc-induced T-ALL model, despite the rapid onset 
of the malignant transformation, the disease remained localized and failed to disseminate, 
compared to fish expressing Myc alone. They demonstrated that both human and zebrafish 
T-LBL cells with increased BCL2 levels possess a distinct cellular phenotype including 
impaired vascular invasion, metabolic stress, and autophagy. This T-LBL phenotype 
results from elevated levels of singhosine-1 phosphate receptor 1 (S1P1) and intercellular 
adhesion molecule 1, promoting homotypic cell-cell adhesion and blocking intravasation 
of tumor cells. Treatment with the S1P1-antagonist W146 promotes intravasation of bcl-2-
overexpressing T-LBL cells in zebrafish (Figure 4). Moreover, AKT activation overcomes 
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this intravasation blockade and promotes the rapid dissemination of T-LBL to T-ALL. This 
work elucidated the molecular events underlying the progression of T-LBL to T-ALL and 
helped to explain clinical disparities between these two diseases. 
 
Figure 4: The selective S1P1 antagonist W146 promotes intravasation of bcl-2-
overexpressing T-LBL cells in vivo 
 
(A) Schematic drawing of the experimental strategy. (B–G) Confocal images of EGFP-labeled 
blood vessels (B and E), dsRed2-labeled lymphoma cells (C and F), and the merged images of a 
vehicle-treated (D; n = 29) and a W146-treated transplanted animal (G; n = 18) demonstrate that 
W146 treatment promotes intravasation of bcl-2-overexpressing lymphoma cells (arrowheads) in 
vivo (cf. G to D). Note that W146 treatment also inhibited the in vivo formation of lymphoma cell 
aggregates (cf. F to C). Scale bar for (B)–(G), 10 mM. (Republished with permission from 
Elsevier) [39]. 
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Lineage-specific TEL-JAK2 Action 
 
The human TEL (ETV6)-JAK2 fusion gene results from translocations between JAK2 
(9p24) and TEL (12p13) in cases of T-ALL and CML (Table 1) [89]. In T-ALL cells, this 
translocation fuses exon 5 of TEL with exon 9 of JAK2, whereas the translocation in CML 
cells fuses exon 5 of TEL with exon 12 of JAK2 [89]. To better understand the role of TEL-
JAK2 translocation in leukemogenesis, Onnebo et al. (2012) generated transgenic fish 
expressing the zebrafish tel-jak2 fusion genes, mimicking different leukemic variants of 
human TEL-JAK2 fusion genes [86]. Interestingly, T-ALL-derived tel-jak2 significantly 
perturbed lymphopoiesis. Conversely, CML-derived tel-jak2 led to more myelopoiesis-
associated defects. This experimental evidence supports the idea that TEL-JAK2 exerts 
lineage-specific oncogenic effects. 
 
5. Leukemia Transplantations 
Tumor transplantation is an important technique when studying the pathophysiology of 
cancer. Given their high fecundity and unique imaging advantages, zebrafish make 
excellent transplantation models. Zebrafish tumor cells have been transplanted (i.e. 
allotransplantation, or transplanted from one zebrafish to another) to isolate leukemia-
propagating cells (LPC) and to dissect the molecular mechanisms underlying LPC self-
renewal and drug resistance [112,11]. Moreover, human leukemia cell lines or patient cells 
can be transplanted into zebrafish embryos to generate various xenograft models (i.e. 
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transplanted from one species to another), providing efficient in vivo tools for screening 
novel anti-leukemic therapeutics and determining compound efficacy and toxicity. 
  
 
Syngeneic Transplantation and LPC in Zebrafish T-ALL 
 
Although zebrafish transplantation experiments started as early as the 1990’s [13], a major 
hurdle in their broader application was the need for immunosuppression. Recipient fish are 
often subjected to -irradiation to ablate immune cells and subsequently experience high 
rates of mortality. To overcome this limitation, Smith et al. (2010) generated a Myc-
induced T-ALL model in syngeneic zebrafish (CG1 strain), allowing the transplantation of 
T-ALL cells into immune-matched CG1 sibling fish without the need for 
immunosuppression [112]. This method enabled investigators to quantify the frequency of 
LPC using limiting-dilution cell transplantation in zebrafish. Their research demonstrated 
that T-ALL can be initiated from a single cell, and such LPCs are abundant in T-ALL 
despite differences in their individual tumor-initiating potential. While this research was 
based on T-ALL, the same strategy can be applied to other zebrafish cancer models. The 
identification and study of LPCs may reveal therapeutic strategies directed against the 
cancer stem cells that account for disease relapse. 
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The NOTCH1 and AKT Signaling in LPC 
 
To rapidly assess the functional role of two to three genes in F0 fish without the need for 
stable transgenic fish, Langenau et al. (2008) established a co-injection strategy to 
introduce multiple transgenes into one-cell-stage embryos, permitting transgenes to 
synergize for tumorigenesis [65]. Combining the co-injection strategy with limiting-
dilution cell transplantation, Blackburn et al. (2012) determined the effects of NOTCH1 
signaling on the self-renewal of LPCs [10]. Utilizing a zebrafish Notch1 defective in its 
ability to transcriptionally activate Myc, they demonstrated that NOTCH1 can expand pre-
leukemic clones; however, NOTCH signaling does not increase the overall frequency of 
LPCs, either alone or in collaboration with MYC. These results suggest that the main 
function of NOTCH signaling in T-ALL is to promote the proliferation of premalignant T 
cells, of which only a small number acquire additional mutations and advance to LPCs. 
To identify mutations driving leukemic clonal evolution and intratumoral 
heterogeneity, Blackburn et al. (2014) performed a cell transplantation screen based on 
phenotypic differences among leukemic clones (Figure 5) [11]. Using this approach, after 
serial clonal selection, they identified AKT activation in leukemic cells with elevated LPC 
frequency. Indeed, enforced AKT activation increased LPC frequency by enhancing 
mTOR activity and shortened tumor latency by promoting MYC stability. However, MYC 
stabilization alone was not sufficient to promote LPC frequency. AKT activation promoted 
treatment resistance, and this resistance could be overcome by the combined treatment of 
an AKT inhibitor and dexamethasone. These results indicate that continuous selection in 
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T-ALL cells promotes clonal evolution and disease progression, and that clonal selection 
can occur before therapeutic intervention. 
  
Figure 5: Clonal evolution drives intratumoral heterogeneity and can lead to increased 
LPC frequency 
 
(A) A schematic of the cell transplantation screen designed to identify phenotypic differences 
between single leukemic clones. (B and C) Schematic of results from primary T-ALL #1 (B) and 
T-ALL #9 (C). *Denotes a significant increase in LPC frequency from monoclonal primary to 
secondary transplant (p = 0.02). **Denotes a significant increase in LPC frequency from 
monoclonal primary transplant T-ALL compared with tertiary transplanted leukemia (p < 
0.0001). Clones are color coded based on Tcrβ-rearrangements (Republished with permission 
from Elsevier) [11]. 
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Zebrafish Xenograft Models of Human Leukemia 
 
Xenograft models are widely applied in rodents to investigate tumor proliferation and drug 
sensitivity. Zebrafish embryos are particularly well-suited for xenografting given the 
following: (a) zebrafish lack a mature adaptive immune system until four weeks post-
fertilization [82], allowing transplantation without the need for immunosuppression; (b) 
zebrafish are optically transparent and, as with injected cells, can be specifically labeled 
with various fluorochromes allowing visualization of in vivo cell-cell interactions; and (c) 
zebrafish are highly fecund and inexpensive to maintain, permitting high-throughput drug 
screening. Since 2011, researchers have been transplanting human leukemia cell lines and 
primary leukemic cells into zebrafish embryos (48 hpf) to screen novel compounds and to 
assay drug efficacy and toxicity for preclinical validation (see Section 6). 
 
6. Drug Discovery & Small Molecule Screens 
 
Drug discovery and development is a time-consuming and expensive process, in some 
instances costing upwards of $1 billion over 10-15 years as a drug progresses from early 
target identification through clinical trials and market approval [52]. Current techniques in 
drug discovery allow researchers to generate an enormous number of potential targets for 
further development, but correctly identifying ‘hits’—compounds that will ultimately 
prove successful in clinical trials—continues to pose enormous challenges. Mammalian 
and invertebrate animal models are often used in the screening process, but the mammals 
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are costly and cumbersome, and invertebrates are less physiologically relevant to humans. 
Therefore, non-mammalian vertebrate systems combining high-throughput whole-
organism testing and rapid phenotypic selection—with the added benefit of preliminary 
toxicological readout—hold obvious appeal for improving time- and cost-efficiency. 
Zebrafish are compatible with such a system; they share useful physiological 
characteristics with mammals, their small embryos and juveniles permit multiplex 
techniques, and their adequately developed organs allow toxicities to be identified early 
during screening [140]. Zebrafish drug screens can be performed with chemical libraries 
utilizing wild-type, mutant, transgenic, or xenografted zebrafish embryos. Recent advances 
using zebrafish transgenic and xenograft models of leukemia are discussed as follows.  
 
Small Molecule Screens Using Transgenic Leukemia Models 
 
Chemical library screening for leukemic research began in 2010 when a zebrafish Myc-
induced T-ALL model demonstrated its capacity to recapitulate clinical responses to 
approved therapeutics (e.g. cyclophosphamide, vincristine, and prednisolone) as observed 
in humans [76]. Since then chemical library screening has been applied to zebrafish 
leukemia models including an AML model and multiple T-ALL models [47,101,134]. 
Yeh et al. (2009) performed one of the first chemical library screens with a 
transgenic line aiming to model AML [134]. Their model expressed an oncogenic AML 
driver of hematopoietic differentiation termed AML1-ETO, a fusion protein resulting from 
the t(8;21) translocation (Table 1). The investigators hypothesized that inhibition of the 
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self-renewal ability of hematopoietic stem cells could provide a complementary therapy to 
the inhibition of cell proliferation (a common approach of AML therapy). As described 
earlier (Table 2), the oncogenic AML1-ETO fusion protein was expressed under the hsp70 
promoter in homozygous fish outcrossed with wild-type fish. Their screen utilized five 
heterozygous embryos per well in 96-well plates collectively treated with the SPECTRUM 
compound library—comprised of drugs (60%), natural products (25%), and other bioactive 
components (15%). Plates were heat shocked to induce AE expression within embryos, 
thereafter assayed for phenotypic change. Notably, use of the hsp70 promoter resulted in 
false-positive hits when select screening agents interfered with proteins related to the heat 
shock response; the authors suggest using a different promoter to avoid this pitfall. Follow-
up study with their lead hit—the COX-2 inhibitor nimesulide—identified a previously 
unknown role for COX-2 and β-catenin in AE-mediated hematopoietic differentiation. 
Specifically, nimesulide antagonizes the effects of AML1-ETO on hematopoietic 
differentiation by interrupting the COX-2 dependent β-catenin signaling pathway [134]. 
Therefore, future studies might aim to manipulate COX-2 or β-catenin signaling in AML 
patients with AE-associated pathology. 
Whereas Yeh et al. (2009) performed chemical screening with a library of 
characterized compounds, Ridges et al. (2012) performed the first embryonic zebrafish 
screen using a library of compounds with unknown activity [101,134]. Lacking a model 
manifesting T-ALL during embryogenesis, Ridges et al. used a sequential approach by 
identifying compounds with activity against immature zebrafish T cells—with the idea that 
these cells are most similar to leukemic T lymphoblasts—and thereafter validated hits for 
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anti-neoplastic effect in an adult zebrafish Myc-induced T-ALL model. Their lead hit—
lenaldekar—affects the PI3 kinase/AKT/mTOR pathway and shows selective activity 
against malignant hematopoietic cell lines and primary leukemias [101]. 
Motivated by the need for NOTCH-independent therapeutics, Gutierrez et al. 
(2014) modified a tamoxifen-regulated MYC-induced T-ALL model in a fluorescence-
based screen using dsRed2 expression in thymocytes as a screen read-out (Figure 6) 
[47,66]. With the ability to select for embryos expressing MYC and to image the intensity 
of their thymic dsRed2 fluorescence, they identified perphenazine in a screen of FDA-
approved compounds. Interestingly, in a complementary cell line screen, perphenazine was 
identified for its synergy with NOTCH inhibitors [47]. Perphenazine is best-known as an 
inhibitor of dopamine receptor signaling, but the biologic target mediating its anti-leukemic 
effect appeared to be unrelated to any of its known molecular targets.  Using a novel 
proteomics approach, the tumor suppressor protein phosphatase 2A (PP2A) was found to 
be a novel target of perphenazine that is activated by perphenazine binding.  Their data 
provided evidence that activators of PP2A (e.g. perphenazine) in combination with 
NOTCH-dependent therapeutics might provide an effective T-ALL therapy [47]. 
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Figure 6: Zebrafish screen for small molecules that are toxic to MYC-overexpressing 
thymocytes 
 
(A) Primary screen design. (B) Hits from the primary screen. Arrow denotes the result obtained 
with perphenazine (C). Representative images of DMSO (control) or perphenazine treated 
zebrafish larvae. (D) Dose response curve from secondary screen of perphenazine, with 6 
zebrafish larvae treated per concentration. Drug doses higher than 10 μM induced general toxicity 
(not shown). Error bars = SD (Modified and republished with permission from American Society 
for Clinical Investigation) [47]. 
 
Leukemic Xenograft Models in Drug Discovery 
 
When transgenic zebrafish models for particular leukemias are unavailable for screening, 
zebrafish xenograft models are an alternative and have moved into the mainstream since 
early studies in 2011 [91]. Creating these models involves a labor-intensive xenografting 
procedure, requiring the manual injection of cells prior to experimental manipulation. 
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Pruvot et al. (2011) were the first to establish zebrafish xenograft models of human 
leukemia for drug discovery [91]. After performing zebrafish xenografting, the 
investigators aimed to identify drug-induced decreases in leukemic burden. When flow 
cytometry could not provide sufficient sensitivity to quantify cell proliferation, human L32 
and hypoxanthine-guanine phosphoribosyltransferase gene expression was measured as a 
correlate of drug-induced change in leukemic burden. In an effort to improve this 
quantification, Corkery et al. (2011) developed a methodology to enzymatically dissociate 
drug-treated embryos followed by a semi-automatic quantification of fluorescence 
intensity using a semi-automated macro (Image J) [26]. In this way, leukemic cells could 
be quantified directly. Such studies have provided proof-of-principal and validated the 
utility of zebrafish xenograft models for small molecule screening and anti-leukemic drug 
discovery [26,91]. 
Further advancing the applicability of zebrafish xenografting, Zhang et al. (2014) 
validated a model for the identification of therapeutics targeting leukemic stem cells 
(LSCs), motivated by the clinical persistence of this population following even complete 
cytogenetic responses in CML [115,135]. Their method required LSC-xenografted 
embryos and utilized a novel, highly automated fluorescence-imaging process to determine 
both cancer cell proliferation and cell migration, reducing labor and increasing throughput. 
Though only selective clinical therapeutics were tested (e.g. imatinib, dasatinib, 
parthenolide, etc.), their screen recapitulated these drugs’ inhibition of LSCs in zebrafish 
xenograft models—as previously evidenced by both in vitro and murine studies—thus 
validating their methodology for future anti-LSC drug discovery. 
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The utility and impact of zebrafish-based drug discovery is growing each year. The 
validation of leukemic zebrafish models and their ability to identify lead compounds like 
lenaldekar promote further study and methodological development. Although thousands of 
compounds were screened in the studies discussed above, their setup was largely manual 
and their execution required years of work. High-throughput, fully automated robotic 
methods are in development and promise to automate the selection, placement, and 
injection of zebrafish embryos with DNA and cancer cells, among other desired materials 
[22,113,126].  
 
7. Summary & Future Perspectives 
 
Since the birth of the first zebrafish model of leukemia (T-ALL) in 2003 [66], zebrafish 
have contributed greatly to leukemia research. Multiple different zebrafish lines have been 
generated to model various human leukemias and pre-leukemic diseases, including T-ALL, 
B-ALL, AML, MPN, and MDS. The ease with which the zebrafish can be genetically 
modified and subsequently imaged has allowed investigators to elucidate the molecular 
mechanisms of leukemogenesis, as well as leukemic progression and maintenance. In fact, 
investigation of zebrafish models of leukemia has significantly improved our 
understanding about leukemogenesis. Examples of the advances include: knowledge of a 
shared genetic signature between human and zebrafish T-ALL; the importance of NOTCH 
and MYC in T-ALL pathogenesis [23,38,45,63,66,61,110,122,88,128,129]; the 
contribution of the PTEN-PI3K-AKT pathways to T-ALL drug resistance in the context of 
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MYC-independent disease [45]; BIM-mediated apoptosis as an avenue for therapy [98]; 
genetic factors underlying T-LBL to T-ALL dissemination [39]; and the expression of 
disease-specific fusion proteins  [86]. The development of syngeneic transplantation has 
allowed the isolation of LPCs in zebrafish, and a transplantation-based screen has 
elucidated the role of AKT in LPC clonal evolution and treatment resistance [112,11]. 
Exploiting high-throughput capabilities of the zebrafish system, investigators have 
performed small molecule screens and identified multiple agents with anti-leukemic 
activity, including nimesulide, lenaldekar, and perphenazine [47,101,134]. These advances 
in zebrafish modeling and disease studies have helped to overcome initial skepticism 
concerning their utility in cancer research, establishing an important biomedical role for 
this humble organism. 
 Moving forward, much additional research can be done using the zebrafish. Most 
zebrafish models of leukemia recapitulate human T-ALL, and although models of pre-B-
ALL and AML exist, they have only limited utility. Multiple models of MPN and MDS 
have been generated, but these fish fail to develop AML. This is likely due to single genetic 
manipulation in these zebrafish lines, whereas multiple genetic alterations are required for 
leukemogenesis in humans. Given technological advances, it is now possible to 
simultaneously manipulate multiple genes within the same cell lineage. We anticipate new 
zebrafish models of leukemia—including T-ALL, B-ALL, AML, CLL, and CML—will be 
generated through the use of both transgenic and genome editing technologies, resulting in 
the overexpression of oncogenes and the inactivation of tumor suppressors. These new 
models will provide important mechanistic insight into leukemic initiation and progression. 
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Despite scientists’ current capacity to conduct successful small molecule screening with 
zebrafish embryos, the process remains limited by the necessity to manually deposit 
embryos into multiple wells, as well as the number of embryos that can be manually 
injected when xenograft models are required. Future automation and standardization of 
these procedures will enable truly high-throughput small molecule screening, which could 
eventually contribute to personalized medicine. For example, ex vivo screening of an 
individual patient’s leukemia samples could be applied in a zebrafish xenograft model for 
the testing of multiple drugs and drug combinations, and the readout would inform 
clinicians on measures of both drug potency and toxicity, improving therapy selection on 
a case-by-case basis. 
 Zebrafish have been welcomed into the oncological research community for their 
usefulness in delineating factors contributing to tumorigenesis and treatment resistance, as 
well as for identifying novel agents for experimental therapeutics. However, due to their 
evolutionary distance from humans, results from zebrafish models require further 
validation in mammalian models, particularly as candidate therapeutics approach clinical 
development. Moreover, gene duplication and functional redundancy within the zebrafish 
genome poses a challenge for gene inactivation studies, and antibody production in 
zebrafish remains daunting due to surface glycosylation modification of proteins. Despite 
these limitations, maximizing their strengths in combination with the use of mammalian 
systems, zebrafish will make waves in an ocean of unexploited oncological knowledge, 
especially in leukemic research.  
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